

Department of Pathology
Attendance Report

Date: 06.04.2020

II Year BDS(2018-19 Batch)

Staff: Dr. Vijayashree. R

Timings: 9:30am to 10:30am

Vijayashree R is inviting you to a scheduled Zoom meeting.

Pathology Lecture

Topic: Acute Leukemia

Time: Apr 6, 2020 9:30 AM India.

Join Zoom meeting

<https://us04web.zoom.us/j/4936773461?pwd=ai9XMxJMeGo1NFQzU3VWa2wxSHJLZz09>

Meeting ID: 493 677 3461

Password: 230188

Video link for Acute Leukemia: <https://drive.google.com/file/d/1-6QHFHfJXsxdx63STDN980csZLx6T4gZ/view?usp=drivesdk>

No of students participated: 97

9:45 AM Mon 8 Apr 493-677-3461

Participants (98)

- Sathyapriya L
- Shrini Sumaya
- Shreya Subramanian
- Sindhuja Sri
- Sindhuja R
- Shreya Pinsky
- Sobana Kuppuraman
- sriam T

Genetic Abnormalities

Translocation

- Formation of fusion gene encoding
 - t(9;22) with *BCR-ABL* fusion gene
 - t(8;21) with *RUNX1-RUNX1T1* fusion
 - t(15;17) with *RAR α -PML* fusion
 - t(12;21) with *TEL-AML1* fusion gene
- Over-expression of normal cellular genes
 - t(14;18) with over-expression of *BCL2* in follicular lymphoma
 - t(8;14) with over-expression of *MYC* in Burkitt's

9:45 AM Mon 8 Apr 493-677-3461

Participants (98)

- Rohini Karthik
- Roshni Ramesh
- S.Sandhya Selvakumar
- S.Shahnaz Fatima
- Sandhya Sridhar
- Sangetha Mahendran
- Sanjana Narendran
- Saraswathy Selvam

Genetic Abnormalities

Translocation

- Formation of fusion gene encoding
 - t(9;22) with *BCR-ABL* fusion gene
 - t(8;21) with *RUNX1-RUNX1T1* fusion
 - t(15;17) with *RAR α -PML* fusion
 - t(12;21) with *TEL-AML1* fusion gene
- Over-expression of normal cellular genes
 - t(14;18) with over-expression of *BCL2* in follicular lymphoma
 - t(8;14) with over-expression of *MYC* in Burkitt's

9:45 AM Mon 8 Apr 493-677-3461

Participants (98)

- Nathashri A
- Niranjan N
- Pavithra
- Peraravalan I
- Pon Aruna R
- Pooja Ravi
- Prithvijay V
- Priya Dhanashini

Genetic Abnormalities

Translocation

- Formation of fusion gene encoding
 - t(9;22) with *BCR-ABL* fusion gene
 - t(8;21) with *RUNX1-RUNX1T1* fusion
 - t(15;17) with *RAR α -PML* fusion
 - t(12;21) with *TEL-AML1* fusion gene
- Over-expression of normal cellular genes
 - t(14;18) with over-expression of *BCL2* in follicular lymphoma
 - t(8;14) with over-expression of *MYC* in Burkitt's

9:45 AM Mon 8 Apr 493-677-3461

Participants (98)

- Karthick Sharan
- Kavitha Ky
- Kavya T
- keerthiga MP
- Kirithika Gunasekaran
- Lakshana Dhyaneswaran
- Lakshmi Priya
- Lincy Jenisha

Genetic Abnormalities

Point mutations

Mutations of *p53* & *RAS* or haematopoietic malignancies

Val617Phe mutation of *JAK2* protein in myeloproliferative disorders

Insertion of 4 base pairs with frameshift mutation in nucleophosmin gene in AML

Internal tandem duplication or point mutation in 30% of AML

9:45 AM Mon 8 Apr 493-677-3461

Participants (98)

- Afreen Hassan
- Akarna R
- Akshya Ramanujam
- Akshaya K
- AlaaguPriyadharshini Kas...
- Ameer Nisha
- Anandhi K
- aravind g

Genetic Abnormalities

Nonrandom chromosomal abnormalities commonly translocations are seen in white cell neoplasms.

- The genes that are mutated or over-expressed play **crucial roles** in the growth or survival of the normal cells (MALT1/BCL10)
- Oncoproteins** created by gene fusion block normal maturation. (bcl-6 normally for maturation- post Ag stimulation)
- Proto-oncogenes are often activated in lymphoid cells by errors that **occur during antigen receptor gene rearrangement** and diversification. (c-MYC)

9:45 AM Mon 8 Apr 493-677-3461

Participants (98)

- Harshitha R
- Hyma Edward
- Imra Kaleel
- Janani CK
- Janani J
- Janani K
- Jay Ram
- Joshi.M

Genetic Abnormalities

Point mutations

Mutations of *p53* & *RAS* or haematopoietic malignancies

Val617Phe mutation of *JAK2* protein in myeloproliferative disorders

Insertion of 4 base pairs with frameshift mutation in nucleophosmin gene in AML

Internal tandem duplication or point mutation in 30% of AML

9:45 AM Mon 8 Apr 493-677-3461

Participants (98)

- Ashila S
- Ashish Suresh
- B.Siva priya
- Bhavana Priyanka
- Chathurka Gunasekar
- Danile Rajasekar
- Dayanisha G
- DEEPA NAGAPPAN

Genetic Abnormalities

Point mutations

Mutations of *p53* & *RAS* or haematopoietic malignancies

Val617Phe mutation of *JAK2* protein in myeloproliferative disorders

Insertion of 4 base pairs with frameshift mutation in nucleophosmin gene in AML

Internal tandem duplication or point mutation in 30% of AML

9:45 AM Mon 8 Apr 493-677-3461

Participants (98)

- Deepika Balamurugan
- Gayathri P
- Gayathri Sathiyamoorthy
- Gladson Samuel
- Gokulakannan Ravi
- Gowartheni K A
- Haritha Ravichandran
- Harshini N

Genetic Abnormalities








Point mutations

Mutations of *p53* & *RAS* or haematopoietic malignancies

Val617Phe mutation of *JAK2* protein in myeloproliferative disorders

Insertion of 4 base pairs with frameshift mutation in nucleophosmin gene in AML

Internal tandem duplication or point mutation in 30% of AML



Department of Pathology,
Attendance Report

Date: 08.04.2020

II Year BDS(2018-19 Batch)

Staff: Dr. Vijayashree. R

Timings: 8:30am to 9:30am

Vijayashree R is inviting you to a scheduled Zoom meeting.

Pathology Lecture

Topic: Myeloproliferative disorders

Time: Apr 8, 2020 8:30 AM India.

Join Zoom meeting

<https://us04web.zoom.us/j/4936773461?pwd=j-4zLxpfKG4>

Video link for Myeloproliferative Disorders:

<https://drive.google.com/file/d/1-0oUKxlZofiapwhKQWi1Uz920h8H1P3s/view?usp=drivesdk>

Meeting ID: 493 677 3461

Password: 230188

No of students participated: 93

8:43 AM Wed 8 Apr 493-677-3461

Participants (90)

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Gokulabharani Ravi, Govarthani K A, Haritha Ravichandran, Harshini N, Harshitha R, Hyma Edward, Imra Kaled, Janani Ck

Myeloproliferative

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Gokulabharani Ravi, Govarthani K A, Haritha Ravichandran, Harshini N, Harshitha R, Hyma Edward, Imra Kaled, Janani Ck

8:43 AM Wed 8 Apr 493-677-3461

Participants (90)

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Rishabala, Riyukta Takpur, Rohini Karthik, Rosini Ramesh, S.Sandhya Selvakumar, S.Shahna Fathima, Sandhya Sridhar, Sangetha Mahendran

Myeloproliferative

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Rishabala, Riyukta Takpur, Rohini Karthik, Rosini Ramesh, S.Sandhya Selvakumar, S.Shahna Fathima, Sandhya Sridhar, Sangetha Mahendran

8:43 AM Wed 8 Apr 493-677-3461

Participants (90)

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Pooja Ravi, Prithvij V, Priya Siram, Priyadarshini C, Raghu, Rakshana gnana kamal, Rekha Dillibabu21, Ria Parashar

Myeloproliferative

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Pooja Ravi, Prithvij V, Priya Siram, Priyadarshini C, Raghu, Rakshana gnana kamal, Rekha Dillibabu21, Ria Parashar

8:43 AM Wed 8 Apr 493-677-3461

Participants (89)

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Serjya Narendran, Saraswathy Selvam, Sathyapriya L, Shirin Sumaya, Shreya Subramanian, Sindhuja Sri, Sinduja R, Sobana Kuppuraman

Myeloproliferative

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Serjya Narendran, Saraswathy Selvam, Sathyapriya L, Shirin Sumaya, Shreya Subramanian, Sindhuja Sri, Sinduja R, Sobana Kuppuraman

8:43 AM Wed 8 Apr 493-677-3461

Participants (90)

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Subaram Ganesan, Subashini K, Sugi Rathna, Sujith Supradeep, Sushanthika, Suweadha K, Swetha S, Swethaa Ravichandran

Myeloproliferative

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Subaram Ganesan, Subashini K, Sugi Rathna, Sujith Supradeep, Sushanthika, Suweadha K, Swetha S, Swethaa Ravichandran

8:43 AM Wed 8 Apr 493-677-3461

Participants (90)

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Sugi Rathna, Sujith Supradeep, Sushanthika, Suweadha K, Swetha S, Swethaa Ravichandran, Udhumal Shabika S, Umacharan G B

Myeloproliferative

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Sugi Rathna, Sujith Supradeep, Sushanthika, Suweadha K, Swetha S, Swethaa Ravichandran, Udhumal Shabika S, Umacharan G B

8:43 AM Wed 8 Apr 493-677-3461

Participants (92)

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Krithika Gunasekaran, Lakshana Dhyaneswaran, Lakshikha Sree, Lakshikha, Lancy Jenisha, Lisha Krishnamay, Lovisha Seles, M.S. SNEHA

Polycythaemia - C

Primary	Secondary
F. Vera Rubra	Compensatory inc in erythropoiesis
High altitudes	Increased affinity pulmonary disease
Cardiovascular disease	Heavy smoking
Renal diseases, Tumours (CC, TSG (paraneoplastic))	Men: >35 ml/g women: >32 ml/g
Men: >35 ml/g women: >32 ml/g	Men: 25-35 ml/g Women: 22-32ml/g

Myeloproliferative

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Krithika Gunasekaran, Lakshana Dhyaneswaran, Lakshikha Sree, Lakshikha, Lancy Jenisha, Lisha Krishnamay, Lovisha Seles, M.S. SNEHA

8:43 AM Wed 8 Apr 493-677-3461

Participants (90)

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Chathurika Gunasekar, Danie Rajasekar, Dayanisha G, DEEPA NAGAPPAN, Deepika Balamunagan, Gayathri P, Gayathri Sathiyamoorthy, Gladson Samuel

Myeloproliferative

These 3 disorders are closely Related: in all of them **Janus Kinase 2 (JAK2)** Mutations occur (PRV 100%, ET 50%, PMF 50%); It has Tyrosine kinase activity

Transitional forms exist & evolution from one entity into another occurs

Participants: Chathurika Gunasekar, Danie Rajasekar, Dayanisha G, DEEPA NAGAPPAN, Deepika Balamunagan, Gayathri P, Gayathri Sathiyamoorthy, Gladson Samuel

6:42 AM Wed 6 Apr 493-677-3461

Participants (94)

- Padma Priyadarshi... (me)
- Vijayashree Ragh... (Host)
- Kamalesh Kamalesh
- Priya Dharshini
- AKARNA.R
- Akshya Ramanujam
- Akshaya K
- AlaguPriyadarshini Kasl...

Polycythaemia R

1. Increase in red cell volume
2. **JAK2 mutation** is present in all
3. Deletion of **9p & 20q** may be p
4. Starts insidiously, in late middle
5. Plethoric (abundant) & cyanotic
6. Head ache, dizziness, **hyper** vision, and hematemesis
7. Increased risk of peptic ulcer
8. Bleeding & thrombotic episode after hot bath (BASOPHILS-histaminey and prostaglandin release).
9. Splenomegaly (75%)

6:42 AM Wed 6 Apr 493-677-3461

Participants (94)

- Supth Supradeep
- Sushanthika
- Suvedha K
- Swetha S
- Swetha Ravichandran
- Udhmal Shabika S
- Umacharan G B
- Sriram T

Polycythaemia R

1. Increase in red cell volume
2. **JAK2 mutation** is present in all
3. Deletion of **9p & 20q** may be p
4. Starts insidiously, in late middle
5. Plethoric (abundant) & cyanotic
6. Head ache, dizziness, **hyper** vision, and hematemesis
7. Increased risk of peptic ulcer
8. Bleeding & thrombotic episode after hot bath (BASOPHILS-histaminey and prostaglandin release).
9. Splenomegaly (75%)

6:42 AM Wed 6 Apr 493-677-3461

Participants (90)

- Marajitha Devi M
- Max Milton
- Monica Anbarasan
- Nathashni A
- Niranzan N
- Pavithra
- Peranivalan I
- Pon Aruna R

Myeloproliferative

These 3 disorders are **closely Related**: in all of them **Janus kinase 2 (JAK2) Mutations** occur (PRV 100%, ET 50%, PMF 50%); It has **Tyrosine kinase activity**

Transitional forms exist & evolution from one entity into another occurs

6:42 AM Wed 6 Apr 493-677-3461

Participants (90)

- Anandhi S
- Anandhi Anunachalam
- Anandhi K
- aravind g
- Ashish Suresh
- B.Siva priya
- Bhavana Priyanka

Myeloproliferative

These 3 disorders are **closely Related**: in all of them **Janus kinase 2 (JAK2) Mutations** occur (PRV 100%, ET 50%, PMF 50%); It has **Tyrosine kinase activity**

Transitional forms exist & evolution from one entity into another occurs

6:42 AM Wed 6 Apr 493-677-3461

Participants (90)

- Padma Priyadarshi... (me)
- Vijayashree Ragh... (Host)
- Kamalesh Kamalesh
- AKARNA.R
- Akshya Ramanujam
- Akshaya K
- AlaguPriyadarshini Kasl...
- Ameer Nisha

Myeloproliferative

These 3 disorders are **closely Related**: in all of them **Janus kinase 2 (JAK2) Mutations** occur (PRV 100%, ET 50%, PMF 50%); It has **Tyrosine kinase activity**

Transitional forms exist & evolution from one entity into another occurs

6:42 AM Wed 6 Apr 493-677-3461

Participants (90)

- Janani J
- Janani K
- Jay Ram
- Joshini.M
- kanthia kannan
- Karthick Sharan
- Kaviya Kv
- Kavya T

Myeloproliferative

These 3 disorders are **closely Related**: in all of them **Janus kinase 2 (JAK2) Mutations** occur (PRV 100%, ET 50%, PMF 50%); It has **Tyrosine kinase activity**

Transitional forms exist & evolution from one entity into another occurs

6:42 AM Wed 6 Apr 493-677-3461

Participants (90)

- keerthiga MP
- Kriethika Gunasekaran
- Lakshika Sree
- Lakshmi Priya
- Lincy Jenisha
- Lovisha Seles
- M.S. SNEHA
- Malavika Raja

Myeloproliferative

These 3 disorders are **closely Related**: in all of them **Janus kinase 2 (JAK2) Mutations** occur (PRV 100%, ET 50%, PMF 50%); It has **Tyrosine kinase activity**

Transitional forms exist & evolution from one entity into another occurs